Literature DB >> 19888960

Enhancement of the anti-inflammatory and anti-arthritic effects of theophylline by a low dose of a nitric oxide donor or non-specific nitric oxide synthase inhibitor.

Adel Gomaa1, Mohsen Elshenawy, Noha Afifi, Eman Mohammed, Romany Thabit.   

Abstract

BACKGROUND AND
PURPOSE: Although there are many new specific phosphodiesterase inhibitors with anti-inflammatory activity, none have yet reached the market because of their low therapeutic efficacy. Our study was aimed to evaluate the anti-inflammatory and anti-arthritic effect of an established phosphodiesterase inhibitor, theophylline, and to investigate the effect of the nitric oxide (NO) donor, sodium nitroprusside (SNP) or NO synthase inhibitor, L-N(G)-monomethyl arginine (L-NMMA) on its actions. EXPERIMENTAL APPROACH: The effects of theophylline alone and combined with SNP or L-NMMA on the pathogenesis of adjuvant-induced arthritis in rats were evaluated. KEY
RESULTS: Prophylactic or therapeutic doses of theophylline significantly ameliorated the pathogenesis of adjuvant arthritis in rats as evidenced by a significant decrease in the arthritis index, hind paws volume, ankle joint diameter, fever, body weight loss and hyperalgesia in a dose-dependent manner. Inflammatory cellular infiltrate in synovium of ankle joint and pannus formation were also markedly inhibited. Interleukin-10 (IL-10) levels were significantly increased in arthritic rats given theophylline alone or in combination with either SNP or L-NMMA. Co-administration of a low dose of SNP or L-NMMA enhanced significantly the anti-inflammatory and anti-arthritic effect of theophylline. In contrast, a high dose of SNP counteracted the anti-inflammatory and anti-arthritic effects of theophylline. CONCLUSIONS AND IMPLICATION: These findings confirm the anti-inflammatory and anti-arthritic activities of theophylline and suggest a new approach to enhance the anti-inflammatory and anti-arthritic effects of theophylline would be to administer it in combination with a low dose of a NO donor or a non-specific NO synthase inhibitor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19888960      PMCID: PMC2801224          DOI: 10.1111/j.1476-5381.2009.00468.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

Review 1.  Inflammatory joint disease: clinical, histological, and molecular parameters of acute and chronic inflammation and tissue destruction.

Authors:  Nancy L McCartney-Francis; James Chan; Sharon M Wahl
Journal:  Methods Mol Biol       Date:  2003

2.  Analgesic and anti-inflammatory effects of phosphodiesterase inhibitors.

Authors:  A Kumar; N K Jain; S K Kulkarni
Journal:  Indian J Exp Biol       Date:  2000-01       Impact factor: 0.818

3.  Anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis.

Authors:  D L Boyle; E A Kowaluk; M F Jarvis; C H Lee; S S Bhagwat; M Williams; G S Firestein
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

4.  Effect of phosphodiesterase inhibitors on nitric oxide production by glial cells.

Authors:  Minka Yoshikawa; Akio Suzumura; Atsushi Ito; Tsukasa Tamaru; Tetsuya Takayanagi
Journal:  Tohoku J Exp Med       Date:  2002-03       Impact factor: 1.848

5.  Altered sleep and behavioral patterns of arthritic rats.

Authors:  M L Andersen; S Tufik
Journal:  Sleep Res Online       Date:  2000

6.  Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4.

Authors:  Hermann Tenor; Erik Hedbom; Hans-Jörg Häuselmann; Christian Schudt; Armin Hatzelmann
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

7.  The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat.

Authors:  Omar M E Abdel-Salam; Ayman R Baiuomy; Siham M El-Shenawy; Mahmoud S Arbid
Journal:  Pharmacol Res       Date:  2003-04       Impact factor: 7.658

Review 8.  Regulation of inducible nitric oxide synthase by cAMP-elevating phospho-diesterase inhibitors.

Authors:  M Markovic; Dj Miljkovic; V Trajkovic
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2003-03

9.  Differential effect of phosphodiesterase IV inhibitor RP73401 on various inflammatory and immune responses relevent to rheumatoid arthritis.

Authors:  Jae Youl Cho; Joon Seok Park; Kyong Up Baik; June Goo Lee; Hyun Pyo Kim; Eun Sook Yoo; Myung Hwan Park
Journal:  Pharmacol Res       Date:  2004-05       Impact factor: 7.658

10.  Dual effect of nitric oxide donor on adjuvant arthritis.

Authors:  Adel A Gomaa; Mohsen M Elshenawy; Noha A Afifi; Eman A Mohammed; Romany H Thabit
Journal:  Int Immunopharmacol       Date:  2009-02-02       Impact factor: 4.932

View more
  3 in total

1.  Co-Delivery of Teriflunomide and Methotrexate from Hydroxyapatite Nanoparticles for the Treatment of Rheumatoid Arthritis: In Vitro Characterization, Pharmacodynamic and Biochemical Investigations.

Authors:  Shweta Pandey; Vijay Kumar; Ankita Leekha; Nishant Rai; Farhan Jalees Ahmad; Anita Kamra Verma; Sushama Talegaonkar
Journal:  Pharm Res       Date:  2018-09-05       Impact factor: 4.200

2.  Theophylline exhibits anti-cancer activity via suppressing SRSF3 in cervical and breast cancer cell lines.

Authors:  Yung-Lung Chang; Yu-Juei Hsu; Ying Chen; Yi-Wen Wang; Shih-Ming Huang
Journal:  Oncotarget       Date:  2017-10-03

3.  Aryl-1,3,5-triazine ligands of histamine H4 receptor attenuate inflammatory and nociceptive response to carrageen, zymosan and lipopolysaccharide.

Authors:  Szczepan Mogilski; Monika Kubacka; Dorota Łażewska; Małgorzata Więcek; Monika Głuch-Lutwin; Małgorzata Tyszka-Czochara; Karolina Bukowska-Strakova; Barbara Filipek; Katarzyna Kieć-Kononowicz
Journal:  Inflamm Res       Date:  2016-10-20       Impact factor: 4.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.